Literature DB >> 22138407

The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling.

Stefania Risso Bradley1, Jason M Uslaner, Rose B Flick, Ariel Lee, Kristina M Groover, Peter H Hutson.   

Abstract

Currently prescribed antidepressants affect the reuptake and/or metabolism of biogenic amines. Unfortunately for patients, these treatments require several weeks to produce significant symptom remission. However, recently it has been found that ketamine, a dissociative anesthetic agent that noncompetitively antagonizes NMDA (N-Methyl-d-aspartic acid) receptors, has rapid antidepressant effects at sub-anesthetic doses in clinically depressed patients. These findings indicate that modulation of the glutamatergic system could be an efficient way to achieve antidepressant activity. For this reason, other mechanisms influencing glutamatergic functioning have gained interest. For example, the metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 (N,N'-dibenzyhydryl-ethane-1,2-diamine dihydrochloride) has been shown to be effective in the forced swim and tail-suspension test, behavioral assays sensitive to antidepressants. Here we extend the characterization of AMN082 by demonstrating its effects on differential reinforcement of low rates of responding (DRL)-30, another assay sensitive to antidepressants. Furthermore, we show the engagement of glutamatergic signaling by demonstrating the ability of the selective AMPA (2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid) receptor antagonist NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) to reverse the effects of AMN082 in the tail suspension test. In contrast, NBQX failed to reverse the effects of imipramine in the same behavioral test. Finally, we report that behaviorally efficacious doses of AMN082 modulate phosphorylation of AMPA and NMDA receptor subunits in the hippocampus. These results suggest that the antidepressant-like effects of AMN082 are, at least in part, due to modulation of AMPA and NMDA receptor activity. Therefore, our findings confirm the hypothesis that mGluR7 could represent a novel target for treating depression.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138407     DOI: 10.1016/j.pbb.2011.11.006

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  20 in total

1.  Viral-mediated knockdown of mGluR7 in the nucleus accumbens mediates excessive alcohol drinking and increased ethanol-elicited conditioned place preference in rats.

Authors:  Amine Bahi
Journal:  Neuropsychopharmacology       Date:  2012-07-11       Impact factor: 7.853

2.  Can Metabotropic Glutamate Receptor 7 (mGluR 7) be a Novel Target for Analgesia?

Authors:  Shivaprakash G; Punya Suvarna; Sanjay Hadigal; Priyanka Kamath; Natesh Prabhu; Ashok Shenoy K; Pallavi Lc
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 3.  Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence.

Authors:  Xia Li; Athina Markou
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 4.  Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.

Authors:  Xia Li; Zheng-Xiong Xi; Athina Markou
Journal:  Neuropharmacology       Date:  2012-04-21       Impact factor: 5.250

Review 5.  Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression.

Authors:  Kristie T Ota; Ronald S Duman
Journal:  Neurobiol Dis       Date:  2012-06-09       Impact factor: 5.996

6.  Novel Glutamatergic Treatments for Severe Mood Disorders.

Authors:  Minkyung Park; Mark J Niciu; Carlos A Zarate
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-09

Review 7.  Neuroplasticity and the next wave of antidepressant strategies.

Authors:  Shawn Hayley; Darcy Litteljohn
Journal:  Front Cell Neurosci       Date:  2013-11-20       Impact factor: 5.505

8.  Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7.

Authors:  Nidhi Jalan-Sakrikar; Julie R Field; Rebecca Klar; Margrith E Mattmann; Karen J Gregory; Rocio Zamorano; Darren W Engers; Sean R Bollinger; C David Weaver; Emily L Days; L Michelle Lewis; Thomas J Utley; Miguel Hurtado; Delphine Rigault; Francine Acher; Adam G Walker; Bruce J Melancon; Michael R Wood; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang; Corey R Hopkins; Colleen M Niswender
Journal:  ACS Chem Neurosci       Date:  2014-10-09       Impact factor: 4.418

9.  Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract.

Authors:  Im-Joon Shin; Sung Un Son; Hyunwoo Park; Yoorim Kim; Sung Hyun Park; Kelley Swanberg; Joo-Yeon Shin; Sang-Kyu Ha; Yoonju Cho; Soo-Yong Bang; Jae-Hwan Lew; Seung-Hun Cho; Sungho Maeng
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

10.  The neuroprotective effects of AMN082 on neuronal apoptosis in rats after traumatic brain injury.

Authors:  Chung-Che Lu; Tee-Tau Eric Nyam; Jinn-Rung Kuo; Yao-Lin Lee; Chung-Ching Chio; Che-Chuan Wang
Journal:  BMC Neurosci       Date:  2021-06-25       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.